further develop our technology to enable the development of our potential products

EX-10.8.1 22 f97636orexv10w8w1.txt EXHIBIT 10.8.1 EXHIBIT 10.8.1 AMENDMENT A TO LICENSE AGREEMENT This amendment agreement (the "Amendment A") is entered into by the parties to the existing license agreement effective November 9, 2002 (the "Prior Agreement") between The Regents of the University of California, Department of Energy contract-operators of the Ernest Orlando Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, ("Berkeley Lab"), and Nanosys, Inc., a Delaware corporation ("Licensee") having its principal place of business at 2625 Hanover St., Palo Alto, CA 94304. For good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, the Berkeley Lab and Licensee agree as follows: I. BACKGROUND The Berkeley Lab and Licensee are parties to the Prior Agreement (Berkeley Lab reference L-03-1364) relating generally to certain inventions characterized as nanocrystals and related technology. The Berkeley Lab and Licensee would like to amend the Prior Agreement by way of this Amendment A to include license rights to certain new inventions made in the course of research at Berkeley Lab by [*** Redacted] [*** Redacted] under Berkeley Lab's contract with the United States Department of Energy ("DOE"), relating generally to [*** Redacted] applications of [*** Redacted] and related technology. II. AMENDMENT FEE Licensee shall pay to the Berkeley Lab an Amendment Fee in the amount of [*** Redacted], which accrues upon execution of this Amendment, with [*** Redacted] being payable within [*** Redacted] of the execution of this Amendment, and the remaining [*** Redacted] being payable within [*** Redacted] of the execution date of this Amendment. III. AMENDMENTS TO THE PRIOR AGREEMENT A. Paragraph 5.1 of the Prior Agreement is hereby deleted in its entirety and replaced with the following amended paragraph 5.1: 5.1 Following an initial public offering or series of public offerings of Licensee securities which raises in the aggregate at least $5 million or sale of all or substantially all of the assets or equity of Licensee in a *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. transaction(s) worth at least $5 million ("Offering"), Licensee shall pay to Berkeley Lab the equivalent of the price at the Offering of 70,000 shares of Licensee's common stock. Such payments shall be made in installments with one-third payable 9 months from the Offering, one-third payable 18 months from the Offering and one-third payable 26 months from the Offering. Such payments shall include interest from the date of the Offering to the date such payment is made. Interest shall be compounded on the date such payment is made, and shall be charged at the prime lending rate as published in the Wall Street Journal on the date such payment is made. Licensee shall adjust the 70,000 shares to take into account any stock splits or reverse stock splits since the Effective Date. B. Paragraph 7.4 of the Prior Agreement is hereby amended to insert after paragraph 7.4.l0. the following additional paragraphs: 7.4.11 by [*** Redacted] from the Effective Date, have expended at least [*** Redacted] in the aggregate for direct costs in research and development for technology directly related to [*** Redacted] applications that use Licensed Patents; 7.4.12 by [*** Redacted] from the Effective Date, provide Berkeley Lab with a commercialization plan for [*** Redacted] devices based upon the Licensed Patents; 7.4.13 by [*** Redacted] from the Effective Date, produce in Licensee's facility, a working prototype [*** Redacted] device with at least [*** Redacted]; 7.4.14 by [*** Redacted] from the Effective Date, make commercial sales of Licensed Products that are [*** Redacted] devices C. Paragraph 9.1 of the Prior Agreement is hereby deleted in its entirety and replaced with the following amended paragraph 9.1: 9.1 Licensee shall keep books and records accurately showing all work performed in satisfaction of Article 7 and all Licensed Products manufactured, used, sold or imported under the terms of this Agreement, including without limitation books and records related to licenses for Third Party Patents under paragraph 6.4. Licensee shall preserve those *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. 2 books and records for at least [*** Redacted] years from the date of the work performed or the royalty payment to which they pertain and shall open them to inspection by representatives or agents of Berkeley Lab at reasonable times. Licensee shall render all assistance reasonably requested by Berkeley Lab for the purposes of carrying out such inspections and examination of Licensee's royalty payments and performance under Article 7. D. Exhibit 1 and Exhibit 2 of the Prior Agreement are hereby deleted in their entirety and replaced with the attached amended Exhibit 1 and Exhibit 2. IV. NO OTHER AMENDMENTS Unless expressly amended herein or by subsequent amendments agreed to by the parties in a signed written amendment, all other terms of the Prior Agreement, including but not limited to terms related to interpretation and enforcement of the Prior Agreement, shall remain in full force and effect as originally agreed to in the Prior Agreement, and shall apply equally to the terms of this Amendment A. Berkeley Lab and Licensee execute this Agreement in duplicate originals through their duly authorized respective officers in one or more counterparts, that taken together, are but one instrument. THE RECENTS OF THE UNIVERSITY NANOSYS, INC. OF CALIFORNIA, THROUGH THE ERNEST ORLANDO LAWRENCE BERKELEY NATIONAL LABORATORY By /s/ Piermaria Oddone By /s/ Lawrence Bock ------------------------------- -------------------------- (Signature) (Signature) By Piermaria Oddone By Lawrence Bock Title Deputy Laboratory Director Title President Date 3/18/03 Date 3/20/03 Approved as to form /s/ Glenn R. Woods --------------------- GLENN R. WOODS LAWRENCE BERKELEY NATIONAL LABORATORY *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. 3 EXHIBIT 1 LICENSED (EXCLUSIVE) PATENTS BERKELEY LAB CASE NUMBER PATENT APPLICATION/PATENT [*** Redacted] *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. EXHIBIT 2 LICENSED (FOU EXCLUSIVE) PATENTS BERKELEY LAB PATENT APPLICATION/PATENT CASE NUMBER [*** Redacted] *** Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.